In the shadow of flashy SaaS unicorns, Ennov quietly processes the documentation for 50% of the world's clinical trials. This isn't a growth-hacking startup—it's the invisible infrastructure of pharmaceutical innovation.

"When a pharma giant submits a regulatory filing, Ennov isn't optional infrastructure—it's the system of record that determines whether a drug reaches patients."

The tech stack reveals a pragmatic approach: jQuery, Bootstrap, and Tailwind CSS—tools that prioritize stability over trends. This isn't a company chasing the latest JavaScript framework; it's building systems that must work reliably for decades. When a drug's regulatory submission can take 10 years, your platform can't afford to break.

• Founded by Olivier Pâris with a focus on the full regulatory lifecycle, not just point solutions
• Revenue per employee suggests mature efficiency, not hypergrowth
• 51% direct traffic indicates strong enterprise stickiness and low customer acquisition cost
• Keyword strategy targets specific compliance pain points, not broad market terms